-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Tag Archives: Tekamlo
April 2012 Safety Labeling Changes
Translation The MedWatch April 2012 Safety Labeling Changes posting includes 43 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT. The “Summary Page” provides a listing of drug names … Continue reading
Posted in FDA 2012, FDA Label Change, FDA Safety Communication
Tagged Aceon, Advicor, Aliskiren, Aliskiren and Amlodipine, Aliskiren and Hydrochlorothiazide, Aliskiren and Valsartan, Altace, Altoprev, Amlodipine and Hydrochlorothiazide, Amturnide, April 2012, April 2012 Safety Labeling Changes, Atacand, Beyaz, Candesartan Cilexetil, Certolizumab Pegol, Cimzia, Conjugated Estrogens, Denosumab, Drospirenone and Ethinyl Estradiol, Drospirenone and Ethinyl Estradiol and Levomefolate Calcium, Drospirinenone and Ethinyl Estradiol, drug risks, Drug Safety Communication, egerid, Erlotinib, Estradiol, Everolimus, FDA notice, Insulin Detemir [rDNA origin], Itraconazole, Krystexxa, Levaquin, Levemir, Levofloxacin, liraglutide [rDNA], Lovastatin Extended-release, nelfinavir mesylate, Neupro, Niacin Extended-release/Lovastatin, Nutropin, Omeprazole and Sodium Bicarbonate, palivizumab, Pazopanib, Pegloticase, Perindopril Erbumine, Prandimet, Premarin, Ramipril, Repaglinide and Metformin HCL, Rotigotine, safety label changes, Safety Labeling Changes, Safyral, Somatropin [rDNA origin], Sporanox, Sunitinib Malate, Sutent, Synagis, Tarceva, Tekamlo, Tekturna, Tekturna HCT, USP), Vagifem, Valturna, Victoza, Viracept, Votrient, Xgeva, Yasmin, Yaz, Zortress
Comments Off
Aliskiren containing Medications Drug Safety Comunication
TranslationAliskiren-containing Medications: Drug Safety Comunication – New Warning and Contraindication including: Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide) Tekturna (aliskiren hemifumarate) Tekturna HCT (aliskiren hemifumarate and hydrochlorothiazide) Tekamlo (aliskiren hemifumarate and amlodipine besylate) Valturna (aliskiren hemifumarate and valsartan). Valturna will … Continue reading
Posted in Endocrinology, FDA 2012, FDA Safety Communication, Internal Medicine, Pharmacy
Tagged Aliskiren containing Medications, aliskiren hemifumarate, aliskiren hemifumarate and amlodipine besylate, aliskiren hemifumarate and hydrochlorothiazide, aliskiren hemifumarate and valsartan, amlodipine besylate, Amturnide, and hydrochlorothiazide, Drug Safety Communication, Endocrinology, fda, Internal Medicine, Pharmacy, Tekamlo, Tekturna, Tekturna HCT, Valturna
Comments Off